Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV - Lokugamage, Kumari G.; Hage, Adam; de Vries, Maren; Valero-Jimenez, Ana M.; Schindewolf, Craig; Dittmann, Meike; Rajsbaum, Ricardo; Menachery, Vineet D. (Journal of virology, 2020)
Keywords: Animals; Antiviral Agents - antagonists & inhibitors; Antiviral Agents - metabolism; Antiviral Agents - pharmacology; Betacoronavirus - drug effects; Betacoronavirus - immunology; Betacoronavirus - physiology; Cell Line; Cell Line, Tumor; Chlorocebus aethiops; Humans; Interferon Type I - antagonists & inhibitors; Interferon Type I - immunology; Interferon Type I - metabolism; Interferon Type I - pharmacology; Interferon-alpha - antagonists & inhibitors; Interferon-alpha - immunology; Interferon-alpha - metabolism; Interferon-alpha - pharmacology; Phosphorylation; Recombinant Proteins - pharmacology; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus - drug effects; Severe acute respiratory syndrome-related coronavirus - immunology; Severe acute respiratory syndrome-related coronavirus - physiology; Signal Transduction; Spotlight; STAT1 Transcription Factor - metabolism; Vero Cells; Viral Proteins - chemistry; Viral Proteins - genetics; Viral Proteins - metabolism; Virus Replication - drug effects; Virus-Cell Interactions; COVID-19; IFN; type I interferon; SARS-CoV-2; SARS-CoV; coronavirus; 2019-nCoV; interferon